HKSE:02509 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HKSE:02509 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Qyuns Therapeutics Co's Total Stockholders Equity for the quarter that ended in Dec. 2024 was HK$244.5 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.
Total Stockholders Equity is used to calculate Book Value per Share. Qyuns Therapeutics Co's Book Value per Share for the quarter that ended in Dec. 2024 was HK$1.10. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Qyuns Therapeutics Co's Debt-to-Equity for the quarter that ended in Dec. 2024 was 2.30.
The historical data trend for Qyuns Therapeutics Co's Total Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qyuns Therapeutics Co Annual Data | |||||||||
Trend | Dec21 | Dec22 | Dec23 | Dec24 | |||||
Total Stockholders Equity | 820.82 | 716.61 | 322.41 | 244.47 |
Qyuns Therapeutics Co Quarterly Data | ||||||||
Dec21 | Dec22 | Sep23 | Dec23 | Jun24 | Dec24 | |||
Total Stockholders Equity | Get a 7-Day Free Trial | 716.61 | 425.57 | 322.41 | 395.75 | 244.47 |
Qyuns Therapeutics Co (HKSE:02509) Total Stockholders Equity Explanation
1. Total Stockholders Equity is used to calculate Book Value per Share.
Qyuns Therapeutics Co's Book Value per Share for the quarter that ended in Dec. 2024 is
Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (244.472 | - | 0) | / | 222.072 | |
= | 1.10 |
2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.
Qyuns Therapeutics Co's Debt-to-Equity for the quarter that ended in Dec. 2024 is
Debt-to-Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (226.35 | + | 336.949) | / | 244.472 | |
= | 2.30 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Qyuns Therapeutics Co's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Tai Zhou Yi Yao Cheng Kong Gu Ji Tuan You Xian Gong Si | 2201 Interest of corporation controlled by you | |
Tai Zhou Jian Xin Chuang Ye Tou Zi You Xian Gong Si | 2101 Beneficial owner | |
Hang Zhou Zhong Mei Hua Dong Zhi Yao You Xian Gong Si | 2101 Beneficial owner | |
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si | 2201 Interest of corporation controlled by you | |
Tai Zhou Yi Yao Gao Xin Ji Shu Chan Ye Tou Zi Fa Zhan You Xian Gong Si | 2201 Interest of corporation controlled by you | |
Tai Zhou Yi Yao Gao Xin Qu Hua Yin Jin Rong Tou Zi You Xian Gong Si | 2201 Interest of corporation controlled by you | |
Bei Jing Yuan Da Hua Chuang Tou Zi You Xian Gong Si | 2201 Interest of corporation controlled by you | |
Hua Dong Yi Yao Gu Fen You Xian Gong Si | 2201 Interest of corporation controlled by you | |
Qiu Jiwan | ||
Xu Qiu | ||
Hangzhou Quanyi Investment Management Partnership (general Partnership) | ||
Yu Guo'an | ||
Zhu Jing | ||
Taizhou Xinfu Tongxin Enterprise Management Partnership (limited Partnership) | ||
Sheng Xi Tai |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.